Kurma’s €215m Fund And What It Says About European Funding Environment

Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale.

Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment